TickerFacts.

Company research / PBYI

Puma Biotechnology, Inc. (PBYI)

Build a valuation ↗↓ Download CSV

SEC name PUMA BIOTECHNOLOGY, INC. · CIK 0001401667 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Puma Biotechnology, Inc. reported revenue of $228.37M. Revenue fell 0.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $231.24M.

Key ratios (year ended 2025-12-31)

74.5%
Gross margin (computed)
16.3%
Operating margin
13.6%
Net margin
23.9%
Return on year-end equity
-0.9%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-16

Headquarters locality: Los Angeles · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$231.24M$228.37M$230.47M$235.64M$228.03M$253.16M$225.11M$272.26M$250.99M$27.68Mn/a
Cost of Revenue$58.20M$58.16M$64.40M$62.68M$55.09M$63.70M$39.37M$36.81M$34.62M$5.57Mn/a
Gross Profit (computed)$173.04M$170.21M$166.06M$172.96M$172.94M$189.45M$185.74M$235.44M$216.37M$22.11Mn/a
R&D Expense$71.44M$62.07M$54.94M$50.38M$52.24M$71.87M$97.65M$132.85M$164.85M$207.81M$222.80M
Operating Income$30.44M$37.30M$30.97M$32.64M$23.72M$1.29M-$30.40M-$39.05M-$94.66M-$292.39M-$276.60M
Depreciation & Amortization$10.48M$10.94M$11.52M$11.52M$9.84M$11.30M$10.03M$8.08M$7.38M$2.81M$1.15M
EBITDA$40.91M$48.24M$42.49M$44.16M$33.56M$12.60M-$20.37M-$30.97M-$87.27M-$289.58M-$275.45M
Net Income$26.72M$31.11M$30.28M$21.59M$2.0K-$29.13M-$59.99M-$75.59M-$113.58M-$291.95M-$276.01M
EPS (Diluted)n/a$0.61$0.62$0.45$0.00-$0.72-$1.52n/an/an/an/a
Total Assets$192.74M$216.30M$213.33M$230.53M$222.06M$226.59M$244.22M$234.91M$259.12M$165.53M$252.79M
Total Liabilities$54.19M$85.96M$121.21M$177.09M$200.45M$229.03M$250.17M$217.44M$224.82M$112.22M$42.97M
Long-Term Debtn/a$22.68M$68.00M$102.00M$102.00M$102.00M$84.03M$94.96M$151.89M$48.48Mn/a
Shareholders' Equity$138.54M$130.34M$92.12M$53.44M$21.61M-$2.45M-$5.95M$17.46M$34.31M$53.30M$209.82M
Cash & Equivalents$36.54M$29.64M$69.22M$84.58M$76.20M$63.13M$85.29M$60.04M$108.42M$81.70M$194.49M
Operating Cash Flow$41.15M$41.80M$38.92M$27.01M-$15.83M$20.65M$773.0K$22.38M-$24.11M-$172.47M-$141.69M
Capital Expendituresn/a$71.0K$56.0K$140.0K$0$0$46.0K$306.0K$439.0K$431.0K$4.29M
Free Cash Flown/a$41.73M$38.86M$26.87M-$15.83M$20.65M$727.0K$22.07M-$24.54M-$172.90M-$145.98M
Shares Outstanding51.10M50.41M49.11M47.65M46.35M41.18M40.09M39.20M38.33M37.59M36.83M
Weighted Average Diluted Sharesn/a50.65M49.10M47.55M44.93M40.64M39.58Mn/an/an/an/a
EPS (Basic)n/a$0.62$0.62$0.46$0.00-$0.72-$1.52-$75595.00n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView